oxytocin / Generic mfg. - LARVOL DELTA

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Wake Forest University Health Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Pain

Calcium Carbonate to Augment Labor Contractions (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Weill Medical College of Cornell University | Trial completion date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Obstetrics

Cardiac Autonomic Neural Modulation with Non-Invasive Intranasal Oxytocin during Myocardial Ischemia Reperfusion in a Porcine model (ASA 2025) - "Oxytocin (Pitocin, 10 units per nostril) was administered intranasally...Thus, these findings support the functional improvements measured.Conclusion. Intranasal OXT has the potential to mitigate myocardial ischemia reperfusion-induced sympathoexcitation and ventricular arrhythmias through cardiac autonomic nervous modulation and may be a potential non-invasive therapy."

Non-invasive • Preclinical • Anesthesia • Cardiovascular • Myocardial Ischemia • Reperfusion Injury

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Apr 2026 ➔ Sep 2026 | Trial primary completion date: Mar 2026 ➔ Sep 2026

Trial completion date • Trial primary completion date • Pain

Comparative Study of the Effectiveness of Double Priming Agents in Cervical Ripening and Induction of Labor in Nulliparas. (PubMed, Cureus) - "Over the past several decades, the rate of labor induction has risen significantly, a trend that is unlikely to reverse in light of increasing maternal morbidities. In response, novel strategies are needed to meet the growing demands on labor and delivery units. Combination methods offer a promising approach for expediting labor without adding risks for either the mother or newborn."

Journal • Gynecology • Obstetrics

Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects (clinicaltrials.gov) - P2 | N=7 | Terminated | Sponsor: Wake Forest University Health Sciences | Completed ➔ Terminated; Data from the initial participants were analyzed to support an NIH grant submission, leading to NIH funding of a new protocol to expand on the initial results.

Trial termination • Immunology • Osteoarthritis • Pain • Rheumatology

Oxytocin to Treat PTSD (clinicaltrials.gov) - P2 | N=185 | Completed | Sponsor: VA Office of Research and Development | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Post-traumatic Stress Disorder

Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects (clinicaltrials.gov) - P2 | N=7 | Completed | Sponsor: Wake Forest University Health Sciences | Recruiting ➔ Completed | N=38 ➔ 7

Enrollment change • Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

Predicting oxytocin binding dynamics in receptor genetic variants through computational modeling. (PubMed, NPJ Womens Health) - "Approximately half of U.S. women giving birth annually receive Pitocin, a synthetic form of oxytocin (OXT), yet the optimal dosing remains challenging due to significant individual variability in response...The model revealed differences in time to equilibrium between HEK293T and myometrial cells, distinct dynamics among genetic variants, and that early increases in OXT could partially rescue diminished responses in V281M and E339K variants. This model provides key insights into how genetic variants influence OXT dose responses and offers a framework for tailoring OXT dosing to patient-specific genetic profiles."

Journal

LIFT: Induction of Labor After Cesarean Using Foley Alone vs. Concurrent Foley and Oxytocin (clinicaltrials.gov) - P=N/A | N=100 | Recruiting | Sponsor: University of Pennsylvania | Not yet recruiting ➔ Recruiting

Enrollment open

Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study (clinicaltrials.gov) - P=N/A | N=96 | Suspended | Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Trial completion date: Dec 2024 ➔ Dec 2025 | Recruiting ➔ Suspended | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Trial suspension • Diabetes • Gestational Diabetes • Hematological Disorders • Metabolic Disorders • Postpartum Hemorrhage

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences

New P2 trial • Pain

LIFT: Induction of Labor After Cesarean Using Foley Alone vs. Concurrent Foley and Oxytocin (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: University of Pennsylvania

New trial

Oxytocin Maintenance Infusion in Labouring Women Undergoing Cesarean Delivery: an Up-down Sequential Allocation Study (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Hematological Disorders • Postpartum Hemorrhage

Oxytocin to Treat PTSD (clinicaltrials.gov) - P2 | N=185 | Active, not recruiting | Sponsor: VA Office of Research and Development | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2025 ➔ Aug 2025

Enrollment closed • Trial completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Anesthetic Challenges for a Parturient with Hermansky-Pudlak Syndrome (IARS-SOCCA 2025) - "Pitocin was administered for induction of labor. Patient received 2 units of platelets two hours prior to delivery, as well as 1g of IV tranexamic acid (TXA)... When caring for a parturient with HPS, anesthesiologists should be mindful of the disease pathophysiology and have available alternative pain management plans for labor pain. Vigilance and preparation for adverse outcomes is of most importance in this patient population as a hemorrhagic event could lead to significant maternal morbidity and mortality.4 We stress the importance of having blood products ready, with pre and post-delivery platelet transfusions. As neuraxial anesthesia is absolutely contraindicated, alternative options for labor analgesia including nitrous oxide, systemic opioid administration, and non-opioid pharmacologic management should be offered to patients.3 NSAIDs should be avoided in patients with HPS.5"

Anesthesia • CNS Disorders • Hematological Disorders • Metabolic Disorders • Obstetrics • Pain • Postpartum Hemorrhage

In Vitro Evaluation of Spontaneous and Oxytocin-induced Contractility of Pregnant Human Myometrium During Exposure to Dexmedetomidine (clinicaltrials.gov) - P=N/A | N=50 | Completed | Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Recruiting ➔ Completed

Trial completion • Hematological Disorders • Postpartum Hemorrhage

Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium (clinicaltrials.gov) - P=N/A | N=32 | Recruiting | Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Trial completion date: Oct 2024 ➔ Dec 2025 | Trial primary completion date: Oct 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Hematological Disorders • Postpartum Hemorrhage

Reconceptualizing Intrauterine Resuscitation and Its Short-Term Impact. (PubMed, Diagnostics (Basel)) - "Here, we have created two measures of relative IR effectiveness, determined over a two-hour time frame after Pitocin was first initiated, and asked how fetal risk severity at the time of its initiation impacted IR effectiveness and the clinical decisions made...FRIv2 further improves its physiologic underpinnings. Thus, we propose a new approach to the overall assessment of IR practice."

Journal • Obstetrics

Association of postpartum oxytocin dose and postpartum bleeding outcomes in nulliparous patients at term. (PubMed, Am J Obstet Gynecol) - "High-dose postpartum oxytocin was associated with lower rates of postpartum hemorrhage than lower oxytocin doses. Results appeared consistent for both vaginal and cesarean deliveries (at second stage given primary trial). Given the widespread use of oxytocin globally and its relatively low cost, future multicenter trials of postpartum oxytocin dose are warranted."

Journal • Hematological Disorders • Obesity • Postpartum Hemorrhage

Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity (clinicaltrials.gov) - P2 | N=38 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Jan 2025 ➔ Jan 2026 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects (clinicaltrials.gov) - P2 | N=38 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Mar 2025 ➔ Feb 2026 | Trial primary completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Defining a PK and PD Model for Peripheral Analgesia After IV Oxytocin (clinicaltrials.gov) - P2 | N=25 | Completed | Sponsor: Wake Forest University Health Sciences | Recruiting ➔ Completed

Trial completion • Pain

Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery (clinicaltrials.gov) - P=N/A | N=160 | Recruiting | Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Hematological Disorders • Postpartum Hemorrhage

Interaction between time-of-day and oxytocin efficacy in mice and humans with and without gestational diabetes. (PubMed, bioRxiv) - "Using in vitro studies, a myometrium-specific Bmal1 conditional knockout mouse model, and a mouse model of food-induced gestational diabetes, we find that Bmal1 is crucial for maintaining oxytocin receptor expression and response in the myometrium in mice. These findings also translate to humans, where oxytocin-induced human myometrial cell contraction is time-of-day dependent, and retrospective clinical data suggest that administration of Pitocin in the morning should be considered for pregnant women with gestational diabetes."

Journal • Preclinical • Diabetes • Gestational Diabetes • Metabolic Disorders • ARNTL • BMAL1 • CLOCK